Authors
Eric B Suhler, Alfredo Adán, Antoine P Brézin, Eric Fortin, Hiroshi Goto, Glenn J Jaffe, Toshikatsu Kaburaki, Michal Kramer, Lyndell L Lim, Cristina Muccioli, Quan Dong Nguyen, Joachim Van Calster, Luca Cimino, Martina Kron, Alexandra P Song, Jianzhong Liu, Sophia Pathai, Anne Camez, Ariel Schlaen, Mirjam EJ van Velthoven, Albert T Vitale, Manfred Zierhut, Samir Tari, Andrew D Dick
Publication date
2018/7/1
Journal
Ophthalmology
Volume
125
Issue
7
Pages
1075-1087
Publisher
Elsevier
Description
Purpose
To evaluate safety and efficacy of adalimumab in patients with noninfectious intermediate, posterior, or panuveitis.
Design
Phase 3, open-label, multicenter clinical trial extension (VISUAL III).
Participants
Adults meeting treatment failure (TF) criteria or who completed VISUAL I or II (phase 3, randomized, double-masked, placebo-controlled) without TF.
Methods
Patients received adalimumab 40 mg every other week. Interim follow-up data were described from VISUAL III weeks 0 through 78.
Main Outcome Measures
Disease quiescence, steroid-free quiescence, active inflammatory chorioretinal/retinal vascular lesions, anterior chamber cell grade, vitreous haze grade, best-corrected visual acuity (BCVA), and corticosteroid dose. Binary data were reported using nonresponder imputation (NRI), continuous data using last observation carried forward and as-observed analysis, and corticosteroid dose using …
Scholar articles
EB Suhler, A Adán, AP Brézin, E Fortin, H Goto… - Ophthalmology, 2018